Comparison of ctDNA profiles from HR+/HER2-low and HR+/HER2-0 advanced breast cancer patients

被引：0
|
作者：
Dobric, N. [1 ]
Dandachi, N. [1 ]
Klocker, E. V. [1 ]
Suppan, C. [1 ]
Graf, R. [2 ]
Hasenleithner, S. [2 ]
Jost, P. J. [1 ]
Heitzer, E. [2 ]
Balic, M. [1 ]
机构：
[1] Med Univ Graz, Div Oncol, Dept Internal Med, Graz, Austria
[2] Med Univ Graz, Inst Human Genet, Graz, Austria
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.667
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
491P
引用
收藏
页码：S387 / S387
页数：1
相关论文
共 50 条
  • [31] Comprehensive genomic profiling of advanced HR+/HER2-breast cancer patients using liquid biopsy
    Shao, B.
    Tang, H.
    Liu, X-R.
    Song, G.
    Di, L.
    Xie, F.
    Jia, C.
    Zhang, Y.
    Jia, S.
    Li, H.
    ANNALS OF ONCOLOGY, 2023, 34 : S389 - S389
  • [32] The prognostic impact of BMI in patients with HR+/HER2-advanced breast cancer: a study of the SONABRE registry
    Lammers, Senna W. M.
    Thurisch, Hannah
    Vriens, Ingeborg J. H.
    Meegdes, Marissa
    Engelen, Sanne M. E.
    Erdkamp, Frans L. G.
    Dercksen, M. Wouter
    Vriens, Birgit E. P. J.
    Aaldering, Kirsten N. A.
    Pepels, Manon J. A. E.
    van de Winkel, Linda M. H.
    Peters, Natascha A. J. B.
    Tol, Jolien
    Heijns, Joan B.
    van de Wouw, Agnes J.
    Teeuwen, Nathalie J. A.
    Geurts, Sandra M. E.
    Tjan-Heijnen, Vivianne C. G.
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 203 (02) : 339 - 349
  • [33] The prognostic impact of BMI in patients with HR+/HER2− advanced breast cancer: a study of the SONABRE registry
    Senna W. M. Lammers
    Hannah Thurisch
    Ingeborg J. H. Vriens
    Marissa Meegdes
    Sanne M. E. Engelen
    Frans L. G. Erdkamp
    M. Wouter Dercksen
    Birgit E. P. J. Vriens
    Kirsten N. A. Aaldering
    Manon J. A. E. Pepels
    Linda M. H. van de Winkel
    Natascha A. J. B. Peters
    Jolien Tol
    Joan B. Heijns
    Agnes J. van de Wouw
    Nathalie J. A. Teeuwen
    Sandra M. E. Geurts
    Vivianne C. G. Tjan-Heijnen
    Breast Cancer Research and Treatment, 2024, 203 : 339 - 349
  • [34] A systematic literature review of prognostic factors in patients with HR+/HER2-advanced breast cancer in Japan
    Hattori, Masaya
    Novick, Diego
    Takaura, Kana
    Tanizawa, Yoshinori
    Kawaguchi, Tsutomu
    Haro, Josep Maria
    Monistrol-Mula, Anna
    Onishi, Akira
    Iwata, Hiroji
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (10) : 1498 - 1508
  • [35] The potential markers of endocrine resistance among HR+ /HER2+ breast cancer patients
    K. Chen
    J. Quan
    J. Yang
    Z. Chen
    Clinical and Translational Oncology, 2020, 22 : 576 - 584
  • [36] Cost of recurrence among patients with HR+/HER2-metastatic breast cancer.
    Engel-Nitz, Nicole M.
    Becker, Laura
    Gerdes, Randall
    Hao, Yanni
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [37] Validation of Claims Algorithm to Identify HR+/HER2-Metastatic Breast Cancer Patients
    Chin, Andi
    Wu, Xiyuan
    Ip, Queeny
    Lyle, Derek
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 620 - 620
  • [38] Does chemotherapy benefit patients with HR+/HER2-invasive lobular breast cancer?
    Yaghi, Marita
    Jabbal, Iktej
    Bilani, Nadeem
    Zerdan, Maroun Bou
    Elson, Leah
    Li, Hong
    Saravia, Diana
    Stone, Elizabeth
    Nahleh, Zeina
    CANCER RESEARCH, 2022, 82 (04)
  • [39] The potential markers of endocrine resistance among HR+/HER2+breast cancer patients
    Chen, K.
    Quan, J.
    Yang, J.
    Chen, Z.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2020, 22 (04): : 576 - 584
  • [40] Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
    Ditsch, Nina
    Schmidt, Marcus
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2019, 79 (12) : 1328 - 1335
12345